Document is current

Article History

Received: 4 July 2025

Accepted: 9 November 2025

First Online: 28 November 2025

Declarations

:

: Financial support was provided by the International Alliance of Dermatology Patient Organizations (GlobalSkin) which covered costs for assistance in writing and editing and provided a grant to ensure the paper was published with Open Access.

: Bernd Arents, Ncoza C. Dlova and Rachel Ogola have no conflicts of interest that are directly relevant to the content of this article. Korey Capozza has received advisory board payments from Incyte, Amgen, Pfizer and Astria and is employed by Global Parents for Eczema Research. Melanie Funk is the Managing Director of Eczema Support Australia, a national patient organisation that is mentioned in this article. Eczema Support Australia contributed to the development of the Eczema Management Algorithm and Care Plan cited in the paper. The organisation has received grant funding from the International Alliance of Dermatology Patient Organizations (GlobalSkin) to support patient education and advocacy projects, including a grant for activities surrounding World Atopic Eczema Day. Melanie Funk received no personal financial compensation for participation in this work. Mark J.A. Koh has been a speaker for and received financial grants from LEO, Galderma, GSK, Hyphens, Menarini, Ego, Bioderma, Good Pharma, Sanofi, Pfizer, DKSH, Zuellig, Novartis, AbbVie, Lion, L’Oreal/LaRoche Posay, Quoin and FarmaMondo, has received research grants/funding from Galderma, Hyphens, Amryt, Lilly, AbbVie, Aslan, Bioderma, L’Oreal/LaRoche Posay, Rxilient and Dyamed and is the co-founder, director and medical advisor for DermX.AI.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors contributed to the conceptualisation, drafting and review of this article. All authors read and approved the final version.